Why Don’t Biotech Investors Run Replication Studies Before Investing? – Fight Aging!
Ichor Life Sciences, a pioneer in the longevity industry, operates as a CRO, biotech company, and investor in early-stage startups. Co-founder Kelsey Moody emphasizes the importance of replicating key findings to de-risk investments in the biotech space. By conducting preclinical experiments, Ichor gains insights into potential technical challenges and collaborates efficiently with investee companies. Despite the reproducibility crisis in life sciences, many investors overlook the necessity of running confirming studies due to practical and time constraints. Limited resources, time-consuming study processes, and inadequate scientific expertise within investment firms contribute to the reluctance to invest in replication studies. In a rapidly evolving industry where speed and competitive advantage are paramount, biotech investors face challenges in prioritizing replication studies before making investment decisions.
